Vectorious Medical Technologies, an Israeli company developing a novel cardiac monitoring system for patients suffering from congestive heart failure (CHF), announced today that it has closed a $5 million financing round. Investors in the round included the RadBioMed incubator, which is owned jointly by Yehuda Zisapel and Prof. Nava Zisapel; several private investors, including Zohar Gilon, Gur Muntzer and others; and the U.S.-based Global Cardiovascular Innovation Center (GCIC) of the Cleveland Clinic. Vectorious will use the proceeds for further development as needed to initiate first in-human trials in collaboration with senior cardiologists from America and Israel.
"We are gratified to close this major financing round, a vote of confidence that these strategic investors have made for our groundbreaking CHF management approach," commented Oren Goldstein, Vectorious's founder and CEO. "Our solution will make daily monitoring a routine activity for CHF patients and their physicians, similar to glucose monitoring for diabetes patients. This will lead to reduced CHF morbidities and readmissions, a higher quality-of-life for CHF patients, and huge financial savings to the health system."
Vectorious Medical Technologies